<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">SAGE Open Med</journal-id><journal-id journal-id-type="iso-abbrev">SAGE Open Med</journal-id><journal-id journal-id-type="publisher-id">SMO</journal-id><journal-id journal-id-type="hwp">spsmo</journal-id><journal-title-group><journal-title>SAGE Open Medicine</journal-title></journal-title-group><issn pub-type="epub">2050-3121</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26770683</article-id><article-id pub-id-type="pmc">4687780</article-id><article-id pub-id-type="doi">10.1177/2050312113505559</article-id><article-id pub-id-type="publisher-id">10.1177_2050312113505559</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A walking intervention to reduce inflammation in patients with diabetes and
peripheral arterial/artery disease: A pilot study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Collins</surname><given-names>Tracie C</given-names></name></contrib><contrib contrib-type="author"><name><surname>Twumasi-Ankrah</surname><given-names>Philip</given-names></name></contrib></contrib-group><aff id="aff1-2050312113505559">Department of Preventive Medicine and Public Health, School of
Medicine, The University of Kansas, Wichita, KS, USA</aff><author-notes><corresp id="corresp1-2050312113505559">Tracie C Collins, Department of Preventive Medicine and
Public Health, School of Medicine, The University of Kansas, 1010 N. Kansas St., Ste 1406, Wichita,
KS 67214-3199, USA. Email: <email>tcollins2@kumc.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>9</month><year>2013</year></pub-date><pub-date pub-type="collection"><year>2013</year></pub-date><volume>1</volume><elocation-id>2050312113505559</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 3.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/3.0/">http://www.creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is
attributed as specified on the SAGE and Open Access page(<ext-link ext-link-type="uri" xlink:href="http://www.uk.sagepub.com/aboutus/openaccess.htm">http://www.uk.sagepub.com/aboutus/openaccess.htm</ext-link>).</license-p></license></permissions><abstract><sec id="section1-2050312113505559"><title>Objectives:</title><p>In this pilot study, we sought to determine whether walking reduces inflammation in patients with
diabetes mellitus and peripheral arterial/artery disease.</p></sec><sec id="section2-2050312113505559"><title>Methods:</title><p>We obtained blood samples from patients with diabetes mellitus and peripheral arterial/artery
disease. Intervention participants were advised to walk for 50 min 3 days per week for 6 months.
Participants completed assessments of comorbidities and walking ability. Difference-in-difference
analyses were used to assess the relationship between group assignment and each biomarker over
time.</p></sec><sec id="section3-2050312113505559"><title>Results:</title><p>We randomized 55 participants (control = 25 and intervention = 30). At 6 months and based on
<italic>p</italic> values of &#x0003c;0.20, vascular cellular adhesion molecule, beta-2 microglobulin,
total cholesterol, and triglycerides demonstrated a greater decrease among participants randomized
to the intervention compared to the control.</p></sec><sec id="section4-2050312113505559"><title>Conclusions:</title><p>Walking may reduce inflammation in persons with diabetes mellitus and peripheral arterial/artery
disease. Further research is needed to determine the impact of walking on inflammation in persons
with vascular disease.</p></sec></abstract><kwd-group><kwd>Peripheral arterial/artery disease</kwd><kwd>walking</kwd><kwd>inflammation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January - December 2013</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section5-2050312113505559"><title>Introduction</title><p>Peripheral arterial/artery disease (PAD) results from atherosclerosis of the abdominal aorta and
arteries of the lower extremities. The disease affects 8&#x02013;12 million US adults. One of the most
common risk factors for this disease is diabetes mellitus (DM). Among primary care clinic diabetic
patients aged 50&#x02013;69 years, the prevalence of PAD is as high as 29%.<sup><xref rid="bibr1-2050312113505559" ref-type="bibr">1</xref></sup></p><p>As an atherosclerotic illness, PAD is associated with systemic inflammation. Markers of
inflammation that have been linked to PAD include C-reactive protein (CRP), fibrinogen, soluble
intercellular adhesion molecule (sICAM), soluble vascular cell adhesion molecule (sVCAM), and
interleukin 6 (IL-6).<sup><xref rid="bibr2-2050312113505559" ref-type="bibr">2</xref><xref rid="bibr3-2050312113505559" ref-type="bibr"/><xref rid="bibr4-2050312113505559" ref-type="bibr"/><xref rid="bibr5-2050312113505559" ref-type="bibr"/>&#x02013;<xref rid="bibr6-2050312113505559" ref-type="bibr">6</xref></sup> Convincing evidence exists for the role of CRP in the
development and progression of PAD. In both the Physician&#x02019;s Health Study and the Women&#x02019;s Health
Study,<sup><xref rid="bibr7-2050312113505559" ref-type="bibr">7</xref>,<xref rid="bibr8-2050312113505559" ref-type="bibr">8</xref></sup> participants with the highest CRP levels at baseline
showed up to a sevenfold higher risk of severe PAD compared to participants with lower CRP levels.
Ridker et al.<sup><xref rid="bibr9-2050312113505559" ref-type="bibr">9</xref></sup> identified that
CRP levels were elevated in individuals with claudication and were highest in patients with PAD who
required limb revascularization. In addition, patients with PAD tend to have lower levels of
physical activity as compared to persons without PAD.<sup><xref rid="bibr10-2050312113505559" ref-type="bibr">10</xref>,<xref rid="bibr11-2050312113505559" ref-type="bibr">11</xref></sup> This lower level of activity has been linked, albeit cross-sectionally, to
increased inflammation.<sup><xref rid="bibr5-2050312113505559" ref-type="bibr">5</xref></sup>
Elevated levels of IL-6, sVCAM, and fibrinogen are associated with smaller calf sizes in persons
with PAD.<sup><xref rid="bibr6-2050312113505559" ref-type="bibr">6</xref></sup> Furthermore, higher
sVCAM is associated with lower calf strength. These associations suggest an inverse relationship
between levels of inflammation and favorable calf muscle characteristics, which may contribute to
walking impairment in patients with PAD.<sup><xref rid="bibr6-2050312113505559" ref-type="bibr">6</xref></sup> Additional biomarkers of interest in persons with PAD include lipids, beta-2
microglobulin, monocyte chemoattractant protein (MCP), and albumin. In a pilot work completed by the
principal investigator, high-density lipoprotein (HDL) levels increased while triglyceride levels
decreased in veterans with PAD who were randomized to an unsupervised walking
intervention.<sup><xref rid="bibr12-2050312113505559" ref-type="bibr">12</xref></sup></p><p>Very few studies have assessed the role of walking therapy to improve biomarker levels in persons
with PAD. The objective of this pilot study was to identify the potential effects of a home-based
walking intervention on markers of inflammation (biomarkers) in patients with DM and PAD.</p></sec><sec sec-type="methods" id="section6-2050312113505559"><title>Methods</title><p>The study was conducted during the primary author&#x02019;s (T.C.C.) role as a faculty member at the
University of Minnesota. As such, the Institutional Review Board approved all aspects of the study.
All participants provided informed consent.</p><sec id="section7-2050312113505559"><title>Recruitment, eligibility, and screening</title><p>For this pilot study and with limited funding, we obtained a consecutive subsample from
participants randomized to the parent study. For the parent study, we recruited participants between
January 2007 and March 2009. For this pilot study, participants were recruited from 2008 to 2009.
Participants were recruited from clinics and communities in the Twin Cities metro area of Minnesota
based on self- or physician-referral. We distributed recruitment flyers at health fairs, community
centers, and churches. Additional methods of recruitment included radio advertisements, word of
mouth, and postcards.</p><p>The study included men and women aged 40 years and older with a diagnosis of PAD (resting or
post-exercise ankle brachial index (ABI) of &#x0003c;0.90 or a toe brachial index &#x0003c; 0.7<sup><xref rid="bibr13-2050312113505559" ref-type="bibr">13</xref></sup>), a diagnosis of DM type I or II
(medical history of medication use or diet control for hyperglycemia), and leg symptoms at the time
of enrollment (as captured by the San Diego Claudication Questionnaire (SDCQ)).<sup><xref rid="bibr14-2050312113505559" ref-type="bibr">14</xref></sup> Additional details about eligibility
have been published.<sup><xref rid="bibr15-2050312113505559" ref-type="bibr">15</xref></sup></p><p>Potential participants were screened through telephone interviews. Research staff assessed
medical history and administered the SDCQ. The SDCQ was used to ascertain leg symptoms.<sup><xref rid="bibr14-2050312113505559" ref-type="bibr">14</xref></sup> Additionally, staff administered the
Physical Activity Readiness Questionnaire (PAR-Q), a 7-item questionnaire that detects signs and
symptoms that would contraindicate exercise.<sup><xref rid="bibr16-2050312113505559" ref-type="bibr">16</xref></sup> Eligibility was confirmed with treadmill testing and ABI measurements.<sup><xref rid="bibr17-2050312113505559" ref-type="bibr">17</xref></sup> For persons with an ABI &#x0003e; 1.3,
indicating arterial calcification, we obtained toe brachial indices.<sup><xref rid="bibr13-2050312113505559" ref-type="bibr">13</xref></sup></p></sec><sec id="section8-2050312113505559"><title>Randomization</title><p>Eligible individuals were randomized to intervention or control using permuted blocks with
randomized block sizes 2, 4, 6, or 8 to ensure equal numbers in both groups. Outcomes were analyzed
according to the randomized allocation (intention to treat).</p></sec><sec id="section9-2050312113505559"><title>Standard care</title><p>All participants viewed a 7-min educational video about PAD and its clinical leg symptoms,
life-threatening consequences of PAD (heart attack and stroke), other adverse outcomes (walking
disability), and strategies for disease and risk-factor management (smoking cessation, weight
control, and aerobic activity). After the video, each participant met face-to-face with the research
coordinator. The coordinator queried participants regarding their use of self-management behaviors
(i.e. glucose monitoring and blood pressure monitoring) and provided them with a calendar in which
to document their daily glucose results, weekly blood pressures, and any routine lipid results
provided by their primary care physician.</p></sec><sec id="section10-2050312113505559"><title>Intervention group procedures</title><p>Intervention group subjects participated in a home-based walking program with three components:
(1) a one-on-one interaction with the research coordinator at baseline and following the above
described assessment of self-management behaviors, (2) walking training and weekly group walking
classes with an instructor, and (3) biweekly telephone calls for 6 months. Full details of the
intervention have been published.<sup><xref rid="bibr15-2050312113505559" ref-type="bibr">15</xref></sup></p><p>For the baseline interaction, which occurred on the same day and following the treadmill exam,
discussion focused on the participant&#x02019;s current stage of change,<sup><xref rid="bibr18-2050312113505559" ref-type="bibr">18</xref></sup> as determined from his or her responses to Part 1 of
the Patient-centered Assessment and Counseling for Exercise (PACE) protocol (e.g. &#x0201c;I have been
thinking of starting to exercise in the next 6 months&#x0201d; = 2 or &#x0201c;I&#x02019;ve been doing vigorous exercise 3
or more days per week for the last 6 months or more&#x0201d; = 8).</p><p>Within 1 week of the baseline visit, participants were scheduled to complete two 1-h walking
training sessions, led by an experienced exercise instructor. These sessions served as reinforcement
and facilitated treatment adherence.<sup><xref rid="bibr23-2050312113505559" ref-type="bibr">23</xref></sup> Sessions were held at the University of Minnesota or another location suitable for
walking (e.g. a park). Session one was designed to facilitate interaction among participants. The
exercise instructor asked participants to describe what they hoped to gain from walking for
exercise. The group then discussed strategies for staying in the walking program. Session two was a
practice walking session with the exercise instructor and one or more participants.</p><p>Participants were then encouraged to walk 1 day per week with the study exercise instructor along
with other participants, as available, and to continue walking on their own at least 3 days per week
for a minimum of 4 days of walking each week; participants were advised to walk totally for 50 min
for each session and, using their pedometers, to increase the number of steps by 50 each
session.</p></sec><sec id="section11-2050312113505559"><title>Attention control group procedures</title><p>Individuals randomized to the attention control group participated in bimonthly phone calls with
the research coordinator. During these calls, lasting 10&#x02013;15 min, control group participants shared
and discussed the information documented in their calendars on blood glucose, blood pressure, and
cholesterol levels (if available) and their smoking habits, if applicable. The Exercise Behaviors
Questionnaire was also administered.</p></sec><sec id="section12-2050312113505559"><title>Measures</title><p>At baseline only, the Lifestyle and Clinical Survey (LCS) was administered to ascertain
sociodemographics and comorbidities. This instrument has a summary kappa statistic for reliability
of 0.81 (95% confidence interval (CI) = 0.78&#x02013;0.84) and a summary kappa statistic for validity of
0.58 (95% CI = 0.52&#x02013;0.64).<sup><xref rid="bibr20-2050312113505559" ref-type="bibr">20</xref></sup></p><p>For the parent study, the primary outcome was change from baseline to 6 months in mean maximal
treadmill walking distance, determined from using the Gardner&#x02013;Skinner graded exercise treadmill test
with electrocardiographic monitoring.<sup><xref rid="bibr21-2050312113505559" ref-type="bibr">21</xref></sup></p><p>We captured the participant&#x02019;s ability to walk in the community (i.e. lower limb function) using
the validated interviewer-administered Walking Impairment Questionnaire (WIQ).<sup><xref rid="bibr22-2050312113505559" ref-type="bibr">22</xref></sup> Health-related quality of life was
measured using the Medical Outcomes Study 36-item Short-Form Health Survey (MOS
SF-36<sup>&#x000ae;</sup>).<sup><xref rid="bibr23-2050312113505559" ref-type="bibr">23</xref></sup> We
administered the Stanford Patient Education Research Center Exercise Behavior Survey during each of
the follow-up phone calls. The exercise behavior survey is a 6-item instrument that includes
questions regarding the type of activity and the length of time during which the patient engaged in
that activity during the past week.<sup><xref rid="bibr24-2050312113505559" ref-type="bibr">24</xref></sup></p></sec><sec id="section13-2050312113505559"><title>Biomarkers</title><p>Blood draws were completed following the baseline treadmill visit and again at the 6-month
treadmill visit. A 9-mL serum separator tube was used to collect the original blood sample. The
samples were allowed to clot for 30 min and then centrifuged at 3200 r/min for 10 min. The serum was
aliquoted, using 2.0-mL vials, as follows:</p><list list-type="order" id="list1-2050312113505559"><list-item><p>1.5 mL into one red cap vial, for sICAM, IL-6, sVCAM, and MCP;</p></list-item><list-item><p>1.5 mL into one red cap vial, for beta-2 microglobulin, lipid panel, CRP, and albumin.</p></list-item></list><p>Serum in excess of 3.0 mL was discarded. Samples were stored at &#x02212;80&#x000b0;C and analyzed in batch by
the Collaborative Studies Clinical Laboratory at the University of Minnesota Medical School.</p></sec><sec id="section14-2050312113505559"><title>Adverse events</title><p>During each biweekly phone call, study staff asked whether the patient had developed chest pain,
shortness of breath, or any symptoms requiring hospitalization in the past 2 weeks. If the
participant responded yes, he/she was asked about diagnostic testing, final diagnosis, and whether
the hospital physician stated that the participant could continue in the study. In addition, study
staff ascertained leg symptoms, testing for PAD (e.g. angiography), or invasive therapy for PAD.</p></sec><sec id="section15-2050312113505559"><title>Statistical analysis</title><p>In this analysis, continuous variables were summarized by mean and standard deviation (mean &#x000b1;
SD). Summary of categorical variables included number and percentage of subjects by level of
category of the variable. For the calculation of proportions, denominators were based on non-missing
data unless otherwise stated. To test differences between intervention and control groups, Fisher&#x02019;s
exact chi-square test was used to determine the association between categorical variable and
treatment groups. For categorical variables with more than two levels, the Mantel&#x02013;Haenszel
chi-square test was preferred. For mean differences between groups at baseline, the analysis of
variance (ANOVA) was utilized to determine whether there was any significant difference between
groups. The <italic>p</italic> values for statistical tests are provided.</p><p>For the analyses of changes in biomarker values between treatment and sessions, we utilize the
difference-in-difference (DiD) method. This is a generalization of the usual paired
<italic>t</italic>-test. The DiD analysis proceeds in two stages. First, the obtained differences in
the observed values for the biomarkers at different time points (pre and post). Then, a regular
two-sample <italic>t</italic>-test is run on the two sample differences between the two groups
(treatment vs controls). DiD methods like analysis that involve the time &#x000d7; group interaction term
allow for time-invariant unobserved differences between treatment groups, in particular it removes
differences in unobserved characteristics that are constant over time and that affect individual
biomarker outcomes in a constant way. The observed DiD analysis corresponds to the difference in
least square means analysis using general linear modeling (GLM) and also to the time &#x000d7; group
interaction in ANOVA/GLM.</p><p>Since the distribution of the differences in biomarker values between the pretreatment and
posttreatment sessions was heavily influenced by outliers, we derived the winsorized means for the
test of the difference between mean changes in biomarker values from baseline to 6 months.
Winsorization is a method for reducing the effects of extreme values in the sample, and it is more
robust when data findings can be heavily influenced by outliers.<sup><xref rid="bibr25-2050312113505559" ref-type="bibr">25</xref><xref rid="bibr26-2050312113505559" ref-type="bibr"/><xref rid="bibr27-2050312113505559" ref-type="bibr"/>&#x02013;<xref rid="bibr28-2050312113505559" ref-type="bibr">28</xref></sup> Winsorized means are an attractive alternative to the sample mean for skewed
populations. According to Rivest,<sup><xref rid="bibr27-2050312113505559" ref-type="bibr">27</xref></sup> even in the presence of heavy skewness, the winsorized mean provides, for all
practical purposes, the largest efficiency. Student&#x02019;s <italic>t</italic>-test was used in
determining the differences between the winsorized means of differences in biomarkers values.
Clinically significant differences were assessed at a <italic>p</italic> value &#x0003c; 0.2. All
analyses were conducted using Statistical Analysis System (SAS) (version 9.3; SAS Institute Inc.,
Cary, NC).</p></sec></sec><sec sec-type="results" id="section16-2050312113505559"><title>Results</title><sec id="section17-2050312113505559"><title>Baseline characteristics</title><p>In the larger study, we enrolled 145 participants. For this pilot study, we obtained blood
samples from 55 consecutive participants (control = 25 and intervention = 30). <xref ref-type="table" rid="table1-2050312113505559">Table 1</xref> gives baseline characteristics of
participants within the pilot study. Of the 55 participants, there were 42 men and 13 women; the
mean age was 66.7 &#x000b1; 0.7 years. Study participants were predominantly Caucasian (89.1%), had at least
a high school education (89.1%), and were obese (mean body mass index (BMI) of 34.1 &#x000b1; 8.6).</p><table-wrap id="table1-2050312113505559" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline characteristics by randomized group.</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Total (<italic>n</italic> = 55)</th><th align="left" colspan="1" rowspan="1">Control (<italic>n</italic> = 25)</th><th align="left" colspan="1" rowspan="1">Intervention (<italic>n</italic> = 30)</th><th align="left" colspan="1" rowspan="1"><italic>p</italic> value<xref ref-type="table-fn" rid="table-fn3-2050312113505559">*</xref></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age, mean (SD)</td><td colspan="1" rowspan="1">66.7 (10.7)</td><td colspan="1" rowspan="1">66.9 (11.2)</td><td colspan="1" rowspan="1">66.6 (10.4)</td><td colspan="1" rowspan="1">0.9163</td></tr><tr><td colspan="1" rowspan="1">Female, <italic>n</italic> (%)</td><td colspan="1" rowspan="1">13 (23.6)</td><td colspan="1" rowspan="1">5 (20.0)</td><td colspan="1" rowspan="1">8 (26.7)</td><td colspan="1" rowspan="1">0.5623</td></tr><tr><td colspan="5" rowspan="1">Race, <italic>n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Caucasian</td><td colspan="1" rowspan="1">49 (89.1)</td><td colspan="1" rowspan="1">22 (88.0)</td><td colspan="1" rowspan="1">27 (90.0)</td><td colspan="1" rowspan="4">0.3793</td></tr><tr><td colspan="1" rowspan="1">&#x02003;African American</td><td colspan="1" rowspan="1">4 (7.3)</td><td colspan="1" rowspan="1">1 (4.0)</td><td colspan="1" rowspan="1">3 (10.0)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;American Indian<sup><xref ref-type="table-fn" rid="table-fn4-2050312113505559">a</xref></sup></td><td colspan="1" rowspan="1">1 (1.8)</td><td colspan="1" rowspan="1">1 (4.0)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Unknown</td><td colspan="1" rowspan="1">1 (1.8)</td><td colspan="1" rowspan="1">1 (4.0)</td><td colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="1" rowspan="1">Education &#x02265; high school, <italic>n</italic> (%)</td><td colspan="1" rowspan="1">49 (89.1)</td><td colspan="1" rowspan="1">20 (80.0)</td><td colspan="1" rowspan="1">29 (96.7)</td><td colspan="1" rowspan="1">0.0484</td></tr><tr><td colspan="1" rowspan="1">BMI, mean (SD)</td><td colspan="1" rowspan="1">34.1 (8.6)</td><td colspan="1" rowspan="1">33.9 (7.5)</td><td colspan="1" rowspan="1">34.3 (9.6)</td><td colspan="1" rowspan="1">0.7705</td></tr><tr><td colspan="1" rowspan="1">HbA1c, mean (SD)</td><td colspan="1" rowspan="1">7.2 (1.5)</td><td colspan="1" rowspan="1">7.2 (1.2)</td><td colspan="1" rowspan="1">7.3 (1.7)</td><td colspan="1" rowspan="1">0.8367</td></tr><tr><td colspan="1" rowspan="1">Prior MI, <italic>n</italic> (%)</td><td colspan="1" rowspan="1">10 (18.2)</td><td colspan="1" rowspan="1">5 (20.0)</td><td colspan="1" rowspan="1">5 (16.7)</td><td colspan="1" rowspan="1">0.3936</td></tr><tr><td colspan="1" rowspan="1">Current smoker, <italic>n</italic> (%) (<italic>n</italic> = 41)</td><td colspan="1" rowspan="1">5 (12.2)</td><td colspan="1" rowspan="1">1 (5.26)</td><td colspan="1" rowspan="1">4 (18.2)</td><td colspan="1" rowspan="1">0.8212</td></tr><tr><td colspan="1" rowspan="1">Smoked at least 100 cigarettes during lifetime, <italic>n</italic> (%)</td><td colspan="1" rowspan="1">41 (74.5)</td><td colspan="1" rowspan="1">19 (76.0)</td><td colspan="1" rowspan="1">22 (73.3)</td><td colspan="1" rowspan="1">0.8212</td></tr><tr><td colspan="5" rowspan="1">Number of cigarettes smoked per day, <italic>n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;0&#x02013;4</td><td colspan="1" rowspan="1">1 (2.6)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">1 (5.0)</td><td colspan="1" rowspan="1">0.4996</td></tr><tr><td colspan="1" rowspan="1">&#x02003;5&#x02013;15</td><td colspan="1" rowspan="1">12 (30.8)</td><td colspan="1" rowspan="1">7 (36.8)</td><td colspan="1" rowspan="1">5 (25.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;One pack per day</td><td colspan="1" rowspan="1">9 (23.1)</td><td colspan="1" rowspan="1">3 (15.8)</td><td colspan="1" rowspan="1">6 (30.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;More than one pack per day</td><td colspan="1" rowspan="1">17 (43.5)</td><td colspan="1" rowspan="1">9 (47.4)</td><td colspan="1" rowspan="1">8 (40.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Resting ABI, mean (SD)</td><td colspan="1" rowspan="1">&#x02013;</td><td colspan="1" rowspan="1">0.72 (1.2)</td><td colspan="1" rowspan="1">0.73 (1.7)</td><td colspan="1" rowspan="1">0.8861</td></tr><tr><td colspan="1" rowspan="1">Renal insufficiency, <italic>n</italic> (%)</td><td colspan="1" rowspan="1">2 (3.6)</td><td colspan="1" rowspan="1">1 (4.0)</td><td colspan="1" rowspan="1">1 (3.3)</td><td colspan="1" rowspan="1">0.8954</td></tr><tr><td colspan="1" rowspan="1">Hypertension, <italic>n</italic> (%)</td><td colspan="1" rowspan="1">42 (76.4)</td><td colspan="1" rowspan="1">19 (76.0)</td><td colspan="1" rowspan="1">23 (76.67)</td><td colspan="1" rowspan="1">0.9538</td></tr><tr><td colspan="1" rowspan="1">High blood cholesterol, <italic>n</italic> (%)</td><td colspan="1" rowspan="1">37 (67.3)</td><td colspan="1" rowspan="1">14 (56.0)</td><td colspan="1" rowspan="1">23 (76.7)</td><td colspan="1" rowspan="1">0.1039</td></tr><tr><td colspan="1" rowspan="1">Prior cerebrovascular event or transient ischemic event, <italic>n</italic> (%)</td><td colspan="1" rowspan="1">4 (7.3)</td><td colspan="1" rowspan="1">1 (4.0)</td><td colspan="1" rowspan="1">3 (10.0)</td><td colspan="1" rowspan="1">0.3936</td></tr><tr><td colspan="1" rowspan="1">Medication use for claudication, <italic>n</italic> (%)</td><td colspan="1" rowspan="1">6 (10.9)</td><td colspan="1" rowspan="1">5 (20.0)</td><td colspan="1" rowspan="1">1 (3.3)</td><td colspan="1" rowspan="1">0.0484</td></tr><tr><td colspan="1" rowspan="1">Treadmill walk, maximum pain distance, m</td><td colspan="1" rowspan="1">414.4 (241.4)</td><td colspan="1" rowspan="1">386.2 (257.5)</td><td colspan="1" rowspan="1">434.5 (241.4)</td><td colspan="1" rowspan="1">0.4983</td></tr><tr><td colspan="1" rowspan="1">Treadmill walk, onset of pain distance, m</td><td colspan="1" rowspan="1">144.8 (144.8)</td><td colspan="1" rowspan="1">128.7 (112.6)</td><td colspan="1" rowspan="1">160.9 (160.9)</td><td colspan="1" rowspan="1">0.5491</td></tr><tr><td colspan="1" rowspan="1">Exercise behavior score</td><td colspan="1" rowspan="1">16.6 (14.7)</td><td colspan="1" rowspan="1">16.2 (15.1)</td><td colspan="1" rowspan="1">16.9 (14.5)</td><td colspan="1" rowspan="1">0.8179</td></tr><tr><td colspan="5" rowspan="1">WIQ<sup><xref ref-type="table-fn" rid="table-fn5-2050312113505559">b</xref></sup></td></tr><tr><td colspan="1" rowspan="1">&#x02003;Walking distance</td><td colspan="1" rowspan="1">43.6 (31.7)</td><td colspan="1" rowspan="1">39.7 (30.5)</td><td colspan="1" rowspan="1">46.8 (32.8)</td><td colspan="1" rowspan="1">0.7147</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Walking speed</td><td colspan="1" rowspan="1">43.9 (26.6)</td><td colspan="1" rowspan="1">46.6 (28.9)</td><td colspan="1" rowspan="1">41.6 (24.7)</td><td colspan="1" rowspan="1">0.3374</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Stair climbing</td><td colspan="1" rowspan="1">47.4 (30.8)</td><td colspan="1" rowspan="1">50.7 (29.4)</td><td colspan="1" rowspan="1">44.7 (32.2)</td><td colspan="1" rowspan="1">0.4729</td></tr><tr><td colspan="5" rowspan="1">MOS SF-36, mean (SD)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Physical functioning</td><td colspan="1" rowspan="1">38.3 (9.5)</td><td colspan="1" rowspan="1">39.5 (9.04)</td><td colspan="1" rowspan="1">37.2 (9.9)</td><td colspan="1" rowspan="1">0.3776</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Role&#x02014;physical</td><td colspan="1" rowspan="1">40.2 (14.9)</td><td colspan="1" rowspan="1">41.6 (14.2)</td><td colspan="1" rowspan="1">38.9 (15.7)</td><td colspan="1" rowspan="1">0.8091</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Bodily pain</td><td colspan="1" rowspan="1">46.2 (9.4)</td><td colspan="1" rowspan="1">47.0 (9.0)</td><td colspan="1" rowspan="1">45.6 (9.8)</td><td colspan="1" rowspan="1">0.5130</td></tr><tr><td colspan="1" rowspan="1">&#x02003;General health</td><td colspan="1" rowspan="1">43.6 (9.4)</td><td colspan="1" rowspan="1">42.9 (8.9)</td><td colspan="1" rowspan="1">44.3 (9.9)</td><td colspan="1" rowspan="1">0.4375</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Vitality</td><td colspan="1" rowspan="1">45.0 (13.2)</td><td colspan="1" rowspan="1">43.1 (12.4)</td><td colspan="1" rowspan="1">46.6 (13.9)</td><td colspan="1" rowspan="1">0.4660</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Social functioning</td><td colspan="1" rowspan="1">50.8 (8.5)</td><td colspan="1" rowspan="1">51.6 (8.5)</td><td colspan="1" rowspan="1">50.1 (8.7)</td><td colspan="1" rowspan="1">0.7280</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Role&#x02014;emotional</td><td colspan="1" rowspan="1">19.3 (3.0)</td><td colspan="1" rowspan="1">19.3 (2.7)</td><td colspan="1" rowspan="1">19.3 (3.2)</td><td colspan="1" rowspan="1">0.8034</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mental health</td><td colspan="1" rowspan="1">29.5 (12.7)</td><td colspan="1" rowspan="1">28.5 (13.1)</td><td colspan="1" rowspan="1">30.3 (12.6)</td><td colspan="1" rowspan="1">0.5409</td></tr><tr><td colspan="5" rowspan="1">Biomarker levels</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Soluble intercellular adhesion molecule</td><td colspan="1" rowspan="1">255.9 (87.4)</td><td colspan="1" rowspan="1">239.9 (58.678)</td><td colspan="1" rowspan="1">263.9 (96.7)</td><td colspan="1" rowspan="1">0.2652</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Interleukin-6</td><td colspan="1" rowspan="1">4.1 (3.5)</td><td colspan="1" rowspan="1">4.5 (3.2)</td><td colspan="1" rowspan="1">3.7 (3.5)</td><td colspan="1" rowspan="1">0.3286</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Soluble vascular cell adhesion molecule</td><td colspan="1" rowspan="1">902.8 (306.6)</td><td colspan="1" rowspan="1">928.6 (301.9)</td><td colspan="1" rowspan="1">877.5 (304.3)</td><td colspan="1" rowspan="1">0.5362</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Monocyte chemoattractant protein</td><td colspan="1" rowspan="1">418.6 (132.4)</td><td colspan="1" rowspan="1">438.9 (139.9)</td><td colspan="1" rowspan="1">402.6 (124.9)</td><td colspan="1" rowspan="1">0.3193</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Beta-2 microglobulin</td><td colspan="1" rowspan="1">3.3 (1.8)</td><td colspan="1" rowspan="1">3.6 (2.1)</td><td colspan="1" rowspan="1">2.9 (1.6)</td><td colspan="1" rowspan="1">0.1586</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Total cholesterol</td><td colspan="1" rowspan="1">171.7 (39.9)</td><td colspan="1" rowspan="1">161.6 (41.4)</td><td colspan="1" rowspan="1">181.9 (40.1)</td><td colspan="1" rowspan="1">0.0729</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Triglycerides</td><td colspan="1" rowspan="1">232.9 (178.1)</td><td colspan="1" rowspan="1">175.1 (120.4)</td><td colspan="1" rowspan="1">272.2 (193.6)</td><td colspan="1" rowspan="1">0.0273</td></tr><tr><td colspan="1" rowspan="1">&#x02003;High-density lipoprotein</td><td colspan="1" rowspan="1">43.8 (15.1)</td><td colspan="1" rowspan="1">44.7 (15.9)</td><td colspan="1" rowspan="1">42.6 (14.1)</td><td colspan="1" rowspan="1">0.6014</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Low-density lipoprotein</td><td colspan="1" rowspan="1">86.2 (30.9)</td><td colspan="1" rowspan="1">80.4 (29.6)</td><td colspan="1" rowspan="1">91.6 (32.7)</td><td colspan="1" rowspan="1">0.2193</td></tr><tr><td colspan="1" rowspan="1">&#x02003;C-reactive protein</td><td colspan="1" rowspan="1">5.0 (5.4)</td><td colspan="1" rowspan="1">5.3 (6.0)</td><td colspan="1" rowspan="1">4.8 (4.9)</td><td colspan="1" rowspan="1">0.6989</td></tr></tbody></table><graphic xlink:href="10.1177_2050312113505559-table1"/></alternatives><table-wrap-foot><fn id="table-fn1-2050312113505559"><p>ABI: ankle brachial index; WIQ: Walking Impairment Questionnaire; BMI: body mass index; MOS
SF-36: Medical Outcomes Study 36-item Short-Form Health Survey; SD: standard deviation; MI:
myocardial infarction.</p></fn><fn id="table-fn2-2050312113505559"><p>For the baseline outcome measures, we present means and SDs.</p></fn><fn id="table-fn3-2050312113505559"><label>*</label><p>Fisher&#x02019;s exact test for categorical variables and <italic>t</italic>-tests for continuous
variables.</p></fn><fn id="table-fn4-2050312113505559"><label>a</label><p>Two answered more than one category; <italic>t</italic>-tests comparing means of the two
randomized groups.</p></fn><fn id="table-fn5-2050312113505559"><label>b</label><p>Each domain is scored on a 0&#x02013;100 scale, 0 representing a complete inability to perform the task
and 100 representing no limitations in walking short and long distances, walking at a fast pace, and
climbing three flights of stairs.</p></fn></table-wrap-foot></table-wrap><p>Atherosclerotic risk factors were common; 41 (74.5%) participants were former or current smokers
and 42 (76.4%) had hypertension.</p><p>At baseline, distance to onset of claudication pain was 144.8 &#x000b1; 144.8 m for all participants.
Control subjects could walk a distance of 128.7 &#x000b1; 112.6 m till onset of claudication pain, whereas
participants in the intervention group could walk 160.9 &#x000b1; 160.9 m (<italic>p</italic> value =
0.5491). The maximal walking distance, that is, the total distance a participant could walk from the
start of the treadmill until maximal leg pain was 414.4 &#x000b1; 241.4 m (control = 386.2 &#x000b1; 257.5;
intervention = 434.5 &#x000b1; 241.4; <italic>p</italic> value = 0.4983). Participants&#x02019; mean score on the
Stanford Patient Education Research Center Exercise Behavior Questionnaire for all participants was
16.6 &#x000b1; 14.7, which is equivalent to fewer than 30 min of exercise per week. Control subjects had a
score of 16.2 &#x000b1; 15.1, while intervention subjects had 16.9 &#x000b1; 14.5 (<italic>p</italic> value =
0.8179).</p><p>Participants&#x02019; normed profile scores on the general purpose SF-36 questionnaire are also detailed
in <xref ref-type="table" rid="table1-2050312113505559">Table 1</xref>. The social functioning
summary score was 50.8 &#x000b1; 8.5. Four subscales were within one SD of the norm: role&#x02014;physical = 40.2 &#x000b1;
14.9, bodily pain = 46.2 &#x000b1; 9.4, general health = 43.6 &#x000b1; 9.4, and vitality 45.0 &#x000b1; 13.2.</p><p><xref ref-type="table" rid="table1-2050312113505559">Table 1</xref> also describes the study
groups using baseline values of outcome measures. At baseline, winsorized mean values for the
biomarkers were as follows: intercellular adhesion molecule (ICAM) = 255.9 &#x000b1; 87.4, IL-6 = 4.1 &#x000b1; 3.5,
vascular cell adhesion molecule (VCAM) = 902.8 &#x000b1; 306.6, MCP-1 = 418.6 &#x000b1; 132.4, beta-2 microglobulin
= 3.3 &#x000b1; 1.8, total cholesterol = 171.7 &#x000b1; 39.9, triglycerides = 232.9 &#x000b1; 178.1, HDL = 3.8 &#x000b1; 15.1,
low-density lipoprotein (LDL) = 86.2 &#x000b1; 30.9, and CRP = 5.0 &#x000b1; 5.4.</p><p>There were no significant differences between the control and intervention groups in baseline
characteristics with the exception in use of cilostazol, which was more commonly used by
participants in the control group (20%) as compared to the intervention group (3.3%).</p></sec><sec id="section18-2050312113505559"><title>Efficacy of intervention</title><p>Considering changes from baseline to 6 months, the effect of the intervention of the biomarkers
under discussion in this presentation is detailed in <xref ref-type="table" rid="table2-2050312113505559">Table 2</xref>. At 6 months and based on <italic>p</italic> values of
&#x0003c;0.20, changes in the winsorized means for VCAM (control, 37.1 &#x000b1; 124.1; intervention, 5.1 &#x000b1; 88.2;
<italic>p</italic> value = 0.20), beta-2 microglobulin (control, 0.3 &#x000b1; 0.9; intervention, 0.2 &#x000b1; 0.5;
<italic>p</italic> value = 0.04), total cholesterol (control, 1.3 &#x000b1; 19.7; intervention, &#x02212;10.1 &#x000b1;
26.3; <italic>p</italic> value = 0.12), and triglycerides (control, &#x02212;0.3 &#x000b1; 62.2; intervention, &#x02212;32.1
&#x000b1; 106.9; <italic>p</italic> value = 0.12) demonstrated a trend toward a greater decrease among
participants in the intervention group as compared to the control group. In addition, there were
decreases in LDL (control, &#x02212;0.7 &#x000b1; 19.2; intervention, &#x02212;1.5 &#x000b1; 13.1; <italic>p</italic> value = 0.62)
and CRP levels (control, &#x02212;0.8 &#x000b1; 3.0; intervention, &#x02212;0.4 &#x000b1; 4.9; <italic>p</italic> value = 0.39).
Even though the changes in biomarker values after 6 months from the baseline for the intervention
compared to the control group are not at levels that would constitute statistical significance, they
are important clinical indicators of the trend in the effect of the intervention on these markers of
inflammation.</p><table-wrap id="table2-2050312113505559" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Comparison of intervention and control groups, change from baseline to 6 months.</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Total, mean (SD)</th><th align="left" colspan="1" rowspan="1">Control, mean (SD)</th><th align="left" colspan="1" rowspan="1">Intervention, mean (SD)</th><th align="left" colspan="1" rowspan="1"><italic>p</italic> value<xref ref-type="table-fn" rid="table-fn7-2050312113505559">*</xref></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Soluble intercellular adhesion molecule</td><td colspan="1" rowspan="1">6.72 (38.5)</td><td colspan="1" rowspan="1">8.4 (36.0)</td><td colspan="1" rowspan="1">4.6 (40.6)</td><td colspan="1" rowspan="1">0.2097</td></tr><tr><td colspan="1" rowspan="1">Interleukin-6</td><td colspan="1" rowspan="1">0.29 (4.6)</td><td colspan="1" rowspan="1">0.1 (5.1)</td><td colspan="1" rowspan="1">0.5 (4.5)</td><td colspan="1" rowspan="1">0.6558</td></tr><tr><td colspan="1" rowspan="1">Soluble vascular cell adhesion molecule</td><td colspan="1" rowspan="1">19.72 (109.8)</td><td colspan="1" rowspan="1">37.1 (124.1)</td><td colspan="1" rowspan="1">5.1 (88.2)</td><td colspan="1" rowspan="1">0.1972</td></tr><tr><td colspan="1" rowspan="1">Monocyte chemoattractant protein</td><td colspan="1" rowspan="1">7.55 (99.4)</td><td colspan="1" rowspan="1">&#x02212;13.1 (106.3)</td><td colspan="1" rowspan="1">37.6 (114.6)</td><td colspan="1" rowspan="1">0.5827</td></tr><tr><td colspan="1" rowspan="1">Beta-2 microglobulin</td><td colspan="1" rowspan="1">0.24 (0.8)</td><td colspan="1" rowspan="1">0.3 (0.9)</td><td colspan="1" rowspan="1">0.2 (0.5)</td><td colspan="1" rowspan="1">0.0329</td></tr><tr><td colspan="1" rowspan="1">Total cholesterol</td><td colspan="1" rowspan="1">&#x02212;5.29 (24.5)</td><td colspan="1" rowspan="1">1.3 (19.7)</td><td colspan="1" rowspan="1">&#x02212;10.1 (26.3)</td><td colspan="1" rowspan="1">0.1231</td></tr><tr><td colspan="1" rowspan="1">Triglycerides</td><td colspan="1" rowspan="1">&#x02212;20.93 (96.4)</td><td colspan="1" rowspan="1">&#x02212;0.3 (62.2)</td><td colspan="1" rowspan="1">&#x02212;32.1 (106.9)</td><td colspan="1" rowspan="1">0.1205</td></tr><tr><td colspan="1" rowspan="1">High-density lipoprotein</td><td colspan="1" rowspan="1">&#x02212;1.0 (6.8)</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">&#x02212;2.7 (5.9)</td><td colspan="1" rowspan="1">0.2747</td></tr><tr><td colspan="1" rowspan="1">Low-density lipoprotein</td><td colspan="1" rowspan="1">&#x02212;1.24 (17.9)</td><td colspan="1" rowspan="1">&#x02212;0.7 (19.2)</td><td colspan="1" rowspan="1">&#x02212;1.5 (13.1)</td><td colspan="1" rowspan="1">0.6182</td></tr><tr><td colspan="1" rowspan="1">C-reactive protein</td><td colspan="1" rowspan="1">&#x02212;0.54 (4.5)</td><td colspan="1" rowspan="1">&#x02212;0.8 (3.0)</td><td colspan="1" rowspan="1">&#x02212;0.4 (4.9)</td><td colspan="1" rowspan="1">0.3853</td></tr></tbody></table><graphic xlink:href="10.1177_2050312113505559-table2"/></alternatives><table-wrap-foot><fn id="table-fn6-2050312113505559"><p>SD: standard deviation.</p></fn><fn id="table-fn7-2050312113505559"><p>*<italic>p</italic> value from a <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section19-2050312113505559"><title>Adverse events</title><p>No unanticipated adverse events were reported among randomized participants.</p></sec></sec><sec sec-type="discussion" id="section20-2050312113505559"><title>Discussion</title><p>Our home-based walking intervention involving minimal supervision reduced total cholesterol,
triglycerides, and surprisingly, HDL in persons with DM and PAD. There were no notable trends for
changes in additional biomarkers (i.e. sICAM, IL-6, sVCAM, CRP, and LDL) comparing the intervention
and control groups. This is one of the first studies, albeit a pilot, to assess the effect of
home-based walking therapy on levels of inflammatory markers in persons with DM and PAD; the
findings here are of profound clinical importance.</p><p>Prior work has demonstrated an association between vascular inflammation, PAD severity, and
maximal treadmill walking distance. In the work by Nylaende et al.,<sup><xref rid="bibr29-2050312113505559" ref-type="bibr">29</xref></sup> fasting blood samples were drawn from 127 participants
with PAD (mean age = 66 years, 36% females); PAD severity was captured by the angiographic score.
Tumor necrosis factor-alpha, IL-6, MCP-1, and CD-40 ligand were all significantly correlated with
PAD severity. After adjustment for age, smoking, DM, hypertension, homocysteine, and
hypercholesterolemia, MCP-1 and CD40L remained statistically significantly associated with PAD
severity. However, IL-6 was found to be inversely correlated with maximal treadmill walking
distance. In our work, we did not find an association between IL-6 and home-based walking.
Similarly, in the work by Schlager et al.,<sup><xref rid="bibr30-2050312113505559" ref-type="bibr">30</xref></sup> supervised exercise training for 6 months was not associated with changes in
markers of inflammation including CRP, IL-6, and soluble P-selectin. In contrast, in the work by
Saetre et al.,<sup><xref rid="bibr31-2050312113505559" ref-type="bibr">31</xref></sup> supervised
exercise training delivered for only 2 months significantly reduced plasma levels of endothelial
inflammatory markers E-selectin and intercellular adhesion molecule-1. Such findings may reflect the
role of exercise to reduce endothelial-specific markers but not more general markers of
atherosclerosis and inflammation.</p><p>Persons randomized to our home-based walking program demonstrated a reduction in triglyceride
levels as compared to participants randomized to our attention control group. This trend has been
demonstrated in prior work denoting the benefits of exercise on lipid profiles.<sup><xref rid="bibr32-2050312113505559" ref-type="bibr">32</xref><xref rid="bibr33-2050312113505559" ref-type="bibr"/><xref rid="bibr34-2050312113505559" ref-type="bibr"/>&#x02013;<xref rid="bibr35-2050312113505559" ref-type="bibr">35</xref></sup> However, surprisingly, HDL did not
increase in response to exercise. Furthermore, although this pilot study was underpowered to observe
statistical significance, there was a greater decrease in HDL among persons in our home-based
walking group as compared to those in our attention control group, which should have clinical
significance in the consideration of low-cost low-intensity treatment options for diabetics with
PAD. Reasons for this decrease in HDL are not clear, but may be a reflection of the higher use of
cilostazol in the control as compared to intervention group. Cilostazol is an oral agent that is
used to improve walking distance in patients with symptomatic PAD.<sup><xref rid="bibr36-2050312113505559" ref-type="bibr">36</xref>,<xref rid="bibr37-2050312113505559" ref-type="bibr">37</xref></sup> In addition to its positive impact on lower limb function, cilostazol is known to
increase HDL.<sup><xref rid="bibr37-2050312113505559" ref-type="bibr">37</xref></sup> Further work
is needed to determine whether these effects are enhanced when combined with walking therapy.</p><p>Limitations of the study include the small sample size. As this was a pilot study, our findings
reflect trends, and further work is needed to definitively address our hypothesis in a larger trial.
Our pilot study is the first to determine the effect of a home-based walking program on inflammatory
markers in persons with DM and PAD.</p></sec></body><back><ack><p>T.C.C. interpreted data and was the lead writer of the manuscript; P.T.-A. led data analysis and
assisted with writing.</p></ack><fn-group><fn fn-type="conflict"><p><bold>Declaration of conflicting interests:</bold> There are no disclosures.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This work was supported by funding from the American Diabetes Association (Clinical Research
Project No. 7-06-CR-10) and from the Minnesota Medical Foundation.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-2050312113505559"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>A</given-names></name><name><surname>Criqui</surname><given-names>M</given-names></name><name><surname>Treat-Jacobson</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Peripheral arterial disease detection, awareness, and treatment in
primary care</article-title>. <source>JAMA</source>
<year>2001</year>; <volume>286</volume>: <fpage>1317</fpage>&#x02013;<lpage>1324</lpage>.<pub-id pub-id-type="pmid">11560536</pub-id></mixed-citation></ref><ref id="bibr2-2050312113505559"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brevetti</surname><given-names>G</given-names></name><name><surname>Martone</surname><given-names>VD</given-names></name><name><surname>de Cristofaro</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>High levels of adhesion molecules are associated with impaired
endothelium-dependent vasodilation in patients with peripheral arterial disease</article-title>.
<source>Thromb Haemost</source>
<year>2001</year>; <volume>85</volume>(<issue>1</issue>):
<fpage>63</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">11204590</pub-id></mixed-citation></ref><ref id="bibr3-2050312113505559"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brevetti</surname><given-names>G</given-names></name><name><surname>Schiano</surname><given-names>V</given-names></name><name><surname>Chiariello</surname><given-names>M</given-names></name></person-group>
<article-title>Cellular adhesion molecules and peripheral arterial
disease</article-title>. <source>Vasc Med</source>
<year>2006</year>; <volume>11</volume>(<issue>1</issue>):
<fpage>39</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">16669412</pub-id></mixed-citation></ref><ref id="bibr4-2050312113505559"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McDermott</surname><given-names>MM</given-names></name><name><surname>Greenland</surname><given-names>P</given-names></name><name><surname>Green</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>D-dimer, inflammatory markers, and lower extremity functioning in
patients with and without peripheral arterial disease</article-title>. <source>Circulation</source>
<year>2003</year>; <volume>107</volume>(<issue>25</issue>):
<fpage>3191</fpage>&#x02013;<lpage>3198</lpage>.<pub-id pub-id-type="pmid">12810614</pub-id></mixed-citation></ref><ref id="bibr5-2050312113505559"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McDermott</surname><given-names>MM</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Corsi</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Patterns of inflammation associated with peripheral arterial
disease: the InCHIANTI study</article-title>. <source>Am Heart J</source>
<year>2005</year>; <volume>150</volume>(<issue>2</issue>):
<fpage>276</fpage>&#x02013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">16086930</pub-id></mixed-citation></ref><ref id="bibr6-2050312113505559"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McDermott</surname><given-names>MM</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Elevated levels of inflammation, D-dimer, and homocysteine are
associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial
disease</article-title>. <source>J Am Coll Cardiol</source>
<year>2007</year>; <volume>50</volume>(<issue>9</issue>):
<fpage>897</fpage>&#x02013;<lpage>905</lpage>.<pub-id pub-id-type="pmid">17719478</pub-id></mixed-citation></ref><ref id="bibr7-2050312113505559"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Stampfer</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Inflammation, aspirin, and the risk of cardiovascular disease in
apparently healthy men</article-title>. <source>N Engl J Med</source>
<year>1997</year>; <volume>336</volume>: <fpage>973</fpage>&#x02013;<lpage>979</lpage>.<pub-id pub-id-type="pmid">9077376</pub-id></mixed-citation></ref><ref id="bibr8-2050312113505559"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P</given-names></name><name><surname>Buring</surname><given-names>J</given-names></name><name><surname>Shih</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Prospective study of C-reactive protein and the risk of future
cardiovascular events among apparently healthy women</article-title>. <source>Circulation</source>
<year>1998</year>; <volume>98</volume>: <fpage>731</fpage>&#x02013;<lpage>733</lpage>.<pub-id pub-id-type="pmid">9727541</pub-id></mixed-citation></ref><ref id="bibr9-2050312113505559"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Stampfer</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Plasma concentrations of C-reactive protein and risk of developing
peripheral vascular disease</article-title>. <source>Circulation</source>
<year>1998</year>; <volume>97</volume>: <fpage>425</fpage>&#x02013;<lpage>428</lpage>.<pub-id pub-id-type="pmid">9490235</pub-id></mixed-citation></ref><ref id="bibr10-2050312113505559"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>TC</given-names></name><name><surname>Petersen</surname><given-names>N</given-names></name><name><surname>Suarez-Almazor</surname><given-names>M</given-names></name></person-group>
<article-title>Peripheral arterial disease symptom subtype and walking
impairment</article-title>. <source>Vasc Med</source>
<year>2005</year>; <volume>10</volume>(<issue>3</issue>):
<fpage>177</fpage>&#x02013;<lpage>183</lpage>.<pub-id pub-id-type="pmid">16235770</pub-id></mixed-citation></ref><ref id="bibr11-2050312113505559"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McDermott</surname><given-names>M</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Leg symptoms, the ankle-brachial index, and walking ability in
patients with peripheral arterial disease</article-title>. <source>J Gen Intern Med</source>
<year>1999</year>; <volume>14</volume>(<issue>3</issue>):
<fpage>173</fpage>&#x02013;<lpage>181</lpage>.<pub-id pub-id-type="pmid">10203623</pub-id></mixed-citation></ref><ref id="bibr12-2050312113505559"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>TC</given-names></name><name><surname>Johnson</surname><given-names>SL</given-names></name><name><surname>Souchek</surname><given-names>J</given-names></name></person-group>
<article-title>Unsupervised walking therapy and atherosclerotic risk-factor
management for patients with peripheral arterial disease: a pilot trial</article-title>. <source>Ann
Behav Med</source>
<year>2007</year>; <volume>33</volume>(<issue>3</issue>):
<fpage>318</fpage>&#x02013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">17600459</pub-id></mixed-citation></ref><ref id="bibr13-2050312113505559"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>AT</given-names></name><name><surname>Haskal</surname><given-names>ZJ</given-names></name><name><surname>Hertzer</surname><given-names>NR</given-names></name><etal/></person-group>
<article-title>ACC/AHA 2005 guidelines for the management of patients with
peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive
summary&#x02014;a collaborative report from the American Association for Vascular Surgery/Society for
Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular
Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice
Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral
Arterial Disease); endorsed by the American Association of Cardiovascular and Pulmonary
Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing;
TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation</article-title>. <source>J Am
Coll Cardiol</source>
<year>2006</year>; <volume>47</volume>(<issue>6</issue>):
<fpage>1239</fpage>&#x02013;<lpage>1312</lpage>.<pub-id pub-id-type="pmid">16545667</pub-id></mixed-citation></ref><ref id="bibr14-2050312113505559"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Criqui</surname><given-names>M</given-names></name><name><surname>Denenberg</surname><given-names>J</given-names></name><name><surname>Bird</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>The correlation between symptoms and non-invasive test results in
patients referred for peripheral arterial disease testing</article-title>. <source>Vasc Med</source>
<year>1996</year>; <volume>1</volume>(<issue>1</issue>):
<fpage>65</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">9546918</pub-id></mixed-citation></ref><ref id="bibr15-2050312113505559"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>TC</given-names></name><name><surname>Lunos</surname><given-names>S</given-names></name><name><surname>Carlson</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Effects of a home-based walking intervention on mobility and quality
of life in people with diabetes and peripheral arterial disease: a randomized controlled
trial</article-title>. <source>Diabetes Care</source>
<year>2011</year>; <volume>34</volume>(<issue>10</issue>):
<fpage>2174</fpage>&#x02013;<lpage>2179</lpage>.<pub-id pub-id-type="pmid">21873560</pub-id></mixed-citation></ref><ref id="bibr16-2050312113505559"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Reading</surname><given-names>J</given-names></name><name><surname>Shephard</surname><given-names>RJ.</given-names></name></person-group>
<article-title>Revision of the Physical Activity Readiness Questionnaire (PAR-Q)</article-title>.
<source>Can J Sport Sci</source>
<year>1992</year>; <volume>17</volume>(<issue>4</issue>):
<fpage>338</fpage>&#x02013;<lpage>345</lpage>.<pub-id pub-id-type="pmid">1330274</pub-id></mixed-citation></ref><ref id="bibr17-2050312113505559"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>TC</given-names></name><name><surname>Petersen</surname><given-names>N</given-names></name><name><surname>Suarez-Almazor</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The prevalence of peripheral arterial disease in a racially diverse
population</article-title>. <source>Arch Intern Med</source>
<year>2003</year>; <volume>163</volume>: <fpage>1469</fpage>&#x02013;<lpage>1474</lpage>.<pub-id pub-id-type="pmid">12824097</pub-id></mixed-citation></ref><ref id="bibr18-2050312113505559"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prochaska</surname><given-names>JO</given-names></name><name><surname>DiClemente</surname><given-names>CC.</given-names></name></person-group>
<article-title>Stages and processes of self-change of smoking: toward an integrative model of
change</article-title>. <source>J Consult Clin Psychol</source>
<year>1983</year>; <volume>51</volume>(<issue>3</issue>):
<fpage>390</fpage>&#x02013;<lpage>395</lpage>.<pub-id pub-id-type="pmid">6863699</pub-id></mixed-citation></ref><ref id="bibr19-2050312113505559"><label>19.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Friedman</surname><given-names>L</given-names></name><name><surname>Furberg</surname><given-names>C</given-names></name><name><surname>DeMets</surname><given-names>D.</given-names></name></person-group>
<article-title>Participant adherence</article-title>. In: <person-group person-group-type="editor"><name><surname>Friedman</surname><given-names>L</given-names></name><name><surname>Furberg</surname><given-names>C</given-names></name><name><surname>DeMets</surname><given-names>D</given-names></name></person-group> (eds) <source>Fundamentals of clinical trials</source>. <edition>3rd ed.</edition>
<publisher-loc>New York</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>,
<year>1999</year>, pp. <fpage>204</fpage>&#x02013;<lpage>220</lpage>.</mixed-citation></ref><ref id="bibr20-2050312113505559"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>TC</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>K</given-names></name><name><surname>Petersen</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>The Lifestyle and Clinical Survey: a pilot study to validate a
medical history questionnaire</article-title>. <source>Fed Pract</source>
<year>2005</year>; <volume>22</volume>(<issue>5</issue>):
<fpage>25</fpage>&#x02013;<lpage>46</lpage>.</mixed-citation></ref><ref id="bibr21-2050312113505559"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gardner</surname><given-names>AW</given-names></name><name><surname>Skinner</surname><given-names>JS</given-names></name><name><surname>Cantwell</surname><given-names>BW</given-names></name><etal/></person-group>
<article-title>Progressive vs single-stage treadmill tests for evaluation of
claudication</article-title>. <source>Med Sci Sports Exerc</source>
<year>1991</year>; <volume>23</volume>(<issue>4</issue>):
<fpage>402</fpage>&#x02013;<lpage>408</lpage>.<pub-id pub-id-type="pmid">2056896</pub-id></mixed-citation></ref><ref id="bibr22-2050312113505559"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Regensteiner</surname><given-names>J</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name><name><surname>Panzer</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Evaluation of walking impairment by questionnaire in patients with
peripheral arterial disease</article-title>. <source>J Vasc Med Biol</source>
<year>1990</year>; <volume>2</volume>(<issue>3</issue>):
<fpage>142</fpage>&#x02013;<lpage>152</lpage>.</mixed-citation></ref><ref id="bibr23-2050312113505559"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Gandek</surname><given-names>B.</given-names></name></person-group>
<article-title>Methods for testing data quality, scaling assumptions, and reliability: the IQOLA
Project approach</article-title>. <source>J Clin Epidemiol</source>
<year>1998</year>; <volume>51</volume>(<issue>11</issue>):
<fpage>945</fpage>&#x02013;<lpage>952</lpage>.<pub-id pub-id-type="pmid">9817111</pub-id></mixed-citation></ref><ref id="bibr24-2050312113505559"><label>24.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Lorig</surname><given-names>K</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Ritter</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Stanford chronic disease self-management study</article-title>. In:
<person-group person-group-type="editor"><name><surname>Lorig</surname><given-names>K</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Ritter</surname><given-names>P</given-names></name><etal/></person-group> (eds) <source>Outcome measures for health education and other health care
interventions</source>. <publisher-loc>Thousand Oaks, CA</publisher-loc>:
<publisher-name>SAGE</publisher-name>, <year>1996</year>, pp.
<fpage>24</fpage>&#x02013;<lpage>25</lpage>.</mixed-citation></ref><ref id="bibr25-2050312113505559"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dixon</surname><given-names>W</given-names></name><name><surname>Tukey</surname><given-names>J.</given-names></name></person-group>
<article-title>Approximate behavior of distribution of Winsorized <italic>t</italic>
(Trimming/Winsorization 2)</article-title>. <source>Technometrics</source>
<year>1968</year>; <volume>10</volume>: <fpage>83</fpage>&#x02013;<lpage>98</lpage>.</mixed-citation></ref><ref id="bibr26-2050312113505559"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hasings</surname><given-names>C</given-names></name><name><surname>Mosteller</surname><given-names>F</given-names></name><name><surname>Tukey</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Low moments for small samples: a comparative study of order
statistics</article-title>. <source>Ann Math Stat</source>
<year>1947</year>; <volume>18</volume>: <fpage>413</fpage>&#x02013;<lpage>426</lpage>.</mixed-citation></ref><ref id="bibr27-2050312113505559"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rivest</surname><given-names>L</given-names></name></person-group>
<article-title>Statistical properties of Winsorized means for skewed
distributions</article-title>. <source>Biometrika</source>
<year>1994</year>; <volume>81</volume>: <fpage>373</fpage>&#x02013;<lpage>383</lpage>.</mixed-citation></ref><ref id="bibr28-2050312113505559"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilcom</surname><given-names>R</given-names></name><name><surname>Keselman</surname><given-names>H</given-names></name></person-group>
<article-title>Modern robust data analysis methods: measures of central
tendency</article-title>. <source>Psychol Methods</source>
<year>2003</year>; <volume>8</volume>: <fpage>254</fpage>&#x02013;<lpage>274</lpage>.<pub-id pub-id-type="pmid">14596490</pub-id></mixed-citation></ref><ref id="bibr29-2050312113505559"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nylaende</surname><given-names>M</given-names></name><name><surname>Kroese</surname><given-names>A</given-names></name><name><surname>Stranden</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Markers of vascular inflammation are associated with the extent of
atherosclerosis assessed as angiographic score and treadmill walking distances in patients with
peripheral arterial occlusive disease</article-title>. <source>Vasc Med</source>
<year>2006</year>; <volume>11</volume>(<issue>1</issue>):
<fpage>21</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">16669409</pub-id></mixed-citation></ref><ref id="bibr30-2050312113505559"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schlager</surname><given-names>O</given-names></name><name><surname>Hammer</surname><given-names>A</given-names></name><name><surname>Giurgea</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Impact of exercise training on inflammation and platelet activation
in patients with intermittent claudication</article-title>. <source>Swiss Med Wkly</source>
<year>2012</year>; <volume>142</volume>: <fpage>w13623</fpage>.<pub-id pub-id-type="pmid">22893497</pub-id></mixed-citation></ref><ref id="bibr31-2050312113505559"><label>31.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saetre</surname><given-names>T</given-names></name><name><surname>Enoksen</surname><given-names>E</given-names></name><name><surname>Lyberg</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Supervised exercise training reduces plasma levels of the
endothelial inflammatory markers E-selectin and ICAM-I in patients with peripheral arterial
disease</article-title>. <source>Angiology</source>
<year>2011</year>; <volume>62</volume>(<issue>4</issue>):
<fpage>301</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">21474466</pub-id></mixed-citation></ref><ref id="bibr32-2050312113505559"><label>32.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G</given-names></name><name><surname>Schena</surname><given-names>F</given-names></name><name><surname>Salvagno</surname><given-names>GL</given-names></name><etal/></person-group>
<article-title>Comparison of the lipid profile and lipoprotein(a) between sedentary
and highly trained subjects</article-title>. <source>Clin Chem Lab Med</source>
<year>2006</year>; <volume>44</volume>(<issue>3</issue>):
<fpage>322</fpage>&#x02013;<lpage>326</lpage>.<pub-id pub-id-type="pmid">16519606</pub-id></mixed-citation></ref><ref id="bibr33-2050312113505559"><label>33.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>TM</given-names></name><name><surname>Su</surname><given-names>SF</given-names></name><name><surname>Hwang</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Differential lipogenic effects of cilostazol and pentoxifylline in
patients with intermittent claudication: potential role for interleukin-6</article-title>.
<source>Atherosclerosis</source>
<year>2001</year>; <volume>158</volume>(<issue>2</issue>):
<fpage>471</fpage>&#x02013;<lpage>476</lpage>.<pub-id pub-id-type="pmid">11583728</pub-id></mixed-citation></ref><ref id="bibr34-2050312113505559"><label>34.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Macera</surname><given-names>CA</given-names></name><name><surname>Hornung</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>Changes in lipids associated with change in regular exercise in
free-living men</article-title>. <source>J Clin Epidemiol</source>
<year>1997</year>; <volume>50</volume>(<issue>10</issue>):
<fpage>1137</fpage>&#x02013;<lpage>1142</lpage>.<pub-id pub-id-type="pmid">9368522</pub-id></mixed-citation></ref><ref id="bibr35-2050312113505559"><label>35.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coghill</surname><given-names>N</given-names></name><name><surname>Cooper</surname><given-names>AR</given-names></name></person-group>
<article-title>The effect of a home-based walking program on risk factors for
coronary heart disease in hypercholesterolaemic men. A randomized controlled trial</article-title>.
<source>Prev Med</source>
<year>2008</year>; <volume>46</volume>(<issue>6</issue>):
<fpage>545</fpage>&#x02013;<lpage>551</lpage>.<pub-id pub-id-type="pmid">18316115</pub-id></mixed-citation></ref><ref id="bibr36-2050312113505559"><label>36.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dawson</surname><given-names>DL</given-names></name><name><surname>Cutler</surname><given-names>BS</given-names></name><name><surname>Meissner</surname><given-names>MH</given-names></name><etal/></person-group>
<article-title>Cilostazol has beneficial effects in treatment of intermittent
claudication: results from a multicenter, randomized, prospective, double-blind
trial</article-title>. <source>Circulation</source>
<year>1998</year>; <volume>98</volume>(<issue>7</issue>):
<fpage>678</fpage>&#x02013;<lpage>686</lpage>.<pub-id pub-id-type="pmid">9715861</pub-id></mixed-citation></ref><ref id="bibr37-2050312113505559"><label>37.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dawson</surname><given-names>DL</given-names></name><name><surname>Cutler</surname><given-names>BS</given-names></name><name><surname>Hiatt</surname><given-names>WR</given-names></name><etal/></person-group>
<article-title>A comparison of cilostazol and pentoxifylline for treating
intermittent claudication</article-title>. <source>Am J Med</source>
<year>2000</year>; <volume>109</volume>(<issue>7</issue>):
<fpage>523</fpage>&#x02013;<lpage>530</lpage>.<pub-id pub-id-type="pmid">11063952</pub-id></mixed-citation></ref></ref-list></back></article>